Pfizer receives CHMP positive opinion for novel COVID-19 oral treatment
Summary : Pfizer Inc. (NYSE: PFE) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
Summary : Pfizer Inc. (NYSE: PFE) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
Summary : Pfizer and Ionis Pharmaceuticals announced that the former is abandoning its vupanorsen program for cardiovascular (CV) risk reduction and severe…
Summary : Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir…
PF-07321332 & Ritonavir (Paxlovid): Pfizer Gets CDSCO Panel Nod To Study For COVID Treatment. The Central Drugs Standard Control Organisation(CDSCO) under Directorate General…
HIGHLIGHTS: Spain’s top research institution struck a licensing deal that paves the way for its COVID-19 antibody test to be produced more…
Abstract: The European Commission has approved Pfizer`s first-of-its-kind oral Janus kinase (JAK) inhibitor XELJANZ® (Tofacitinib) 5 mg twice daily for the treatment…
SYNOPSIS: VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s…
KEYPOINTS: Pfizer announced that its oral antiviral cut the risk of hospitalization or death by 89% in an interim analysis of the…
KEYPOINTS: The UK became the first country to approve Covid-19 antiviral pill, jointly developed by US-based Merck & Co Inc and Ridgeback…
KEYWORDS: Dunad Therapeutics, a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies, announces that it has entered a strategic…